It revealed that suppressing inflammasomes by knocking down Tmem176b in mice or utilizing TMEM176B inhibitors can improve the anti-tumor effect of CD8+ T and the efficacy of anti-CTLA-4 and anti-PD1 therapy (Segovia et al., 2019). This evidence concerns the gene PDCD1 and neoplasm.